Majezik-SR is commonly used to help with providing symptomatic relief, and is relevant for easing symptoms and discomfort in therapeutic domains that involve heightened pain and tissue inflammation. The medication is considered relevant for easing the signs and symptoms of major chronic and acute inflammatory conditions.

The medicine is relevant for conditions characterized by periods of heightened symptoms related to physical discomfort, such as Rheumatoid Arthritis and Osteoarthritis. It may be part of symptomatic management to provide long-lasting symptomatic relief from persistent pain, swelling, and stiffness. It is also applied in scenarios that involve acute or episodic changes, may assist with addressing pain associated with Dysmenorrhea, or in clinical settings related to Tendonitis and Soft Tissue Trauma and plays a role in managing systemic Fever.

“The sustained-release formulation provides support that helps ease the overall symptom burden during symptomatic periods and may help patients cope more steadily with symptom fluctuations.”

Sustained Relief for Inflammatory Symptoms

This medication is commonly used in clinical settings marked by acute or unstable symptom patterns and is relevant for easing symptom clusters, such as pain, swelling, stiffness, and fever, that may become intense or disruptive. This supports the patient during difficult episodes by easing distress and may assist with providing supportive relief when symptoms interfere with routine activities.

Symptom Support Note Majezik-SR supports patients with chronic conditions by offering long-lasting symptomatic relief, which contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. MedlinePlus overview of Flurbiprofen

The regulatory profile for Majezik-SR (Flurbiprofen) is defined by strict eligibility rules established for systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The medication is indicated primarily for use in adults aged 18 and older. It is not indicated for children under the age of 12, as safety and efficacy have not been established in this pediatric population.

Contraindicated Populations (Must Not Use)
Known hypersensitivity to Flurbiprofen, aspirin, or other NSAIDs (including aspirin-sensitive asthma).
History of recurrent peptic ulcer disease, active gastrointestinal bleeding, or perforation.
Severe cardiac, renal, or hepatic failure.
Treatment of pain in the setting of coronary artery bypass graft (CABG) surgery.
Third trimester of pregnancy (starting at 30 weeks gestation).

Eligibility is restricted for several groups. The medicine is not recommended for women who are breastfeeding or attempting to conceive. Special caution and close medical monitoring are necessary for elderly patients, as they are at a greater risk for serious gastrointestinal or renal events. Conditional use is also specified for patients with pre-existing mild-to-moderate organ impairment or established cardiovascular conditions such as uncontrolled hypertension.

Interactions with other medicines and products — official regulatory information for Majezik-SR

---

Interaction Scope

• Medicinal product categories with documented interactions: Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Diuretics, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs).
• Specific interacting medicines (if explicitly listed): Lithium, Methotrexate, Aspirin, Warfarin, Mifepristone.
• Mechanistic basis of interactions (only if stated in label): Pharmacodynamic enhancement of bleeding risk; inhibition of renal prostaglandin synthesis leading to reduced clearance of co-administered substances; Flurbiprofen metabolism via Cytochrome P450 2C9 (CYP2C9).
• Timing-based interaction rules (if applicable): Co-administration with Methotrexate should be avoided within a 24-hour window (before or after) due to the risk of elevated Methotrexate concentrations; use with Mifepristone must be separated by 8–12 days.
• Population-specific interaction notes (if applicable): The interaction risk for deterioration of renal function is noted to be greater in elderly patients when co-administered with ACE Inhibitors or ARBs.
• Interaction-related restrictions: The combination with other systemic NSAIDs or COX-2 inhibitors is contraindicated due to the documented increased risk of gastrointestinal toxicity; Alcohol co-administration is noted to increase the risk of gastrointestinal bleeding.

---

Interaction Classifications (High-Level)

• Interaction severity classification (as defined in official documents): Contraindicated (with other NSAIDs); Requires Caution and Monitoring (with Anticoagulants, Lithium, Methotrexate, Diuretics, ACE Inhibitors/ARBs).
• Regulatory basis (EMA / FDA / etc.): The documented statements are consistent with the prescribing information provided by national and regional regulatory authorities.
• Interaction-context constraints (as defined in official documents): These interactions relate to co-administration and apply primarily to agents affecting renal clearance, platelet function/hemostasis, and blood pressure regulation.

---

Resulting Interaction Structure

Official interaction statements:

• Contraindicated combinations include other NSAIDs due to a documented increased risk of gastrointestinal toxicity.
• Co-administration with Anticoagulants and SSRIs results in a pharmacodynamic enhancement of bleeding risk.
• The medicine reduces the antihypertensive efficacy of ACE Inhibitors, ARBs, and Diuretics, an effect attributed to inhibition of renal prostaglandin synthesis.
• A reduction in renal clearance of Lithium and Methotrexate is documented, resulting in elevated plasma concentrations of these medicines.

Connection to the overall interaction profile:

Regulatory documents define the interaction structure of Majezik-SR based on properties common to NSAIDs, focusing on additive pharmacodynamic effects that increase bleeding risk and effects on renal clearance that modify the exposure of co-administered medicines like Lithium and Methotrexate. These documented patterns necessitate specific timing rules and the official contraindication of co-administration with other substances in the same pharmaceutical class. The profile also details the officially stated outcomes—such as the reduction of antihypertensive or diuretic efficacy—as defined by government regulatory agencies.

COX Enzyme Inhibition: Influencing Inflammatory Mediators

The primary action of Majezik-SR is the reversible inhibition of Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2), an action that blocks the early molecular step in the Arachidonic Acid cascade. This critical enzyme inhibition suppresses the formation of key signaling molecules known as Prostaglandins ( PGs), which are mediators that drive excessive physiological responses in the body.

Altering Nociceptive and Thermoregulatory Pathways

The reduction in PG levels alters two essential systems. Peripherally, it decreases the PG-mediated sensitization of nociceptor nerve endings, thereby limiting signal propagation. Centrally, the mechanism supports the adjustment of the hypothalamic set-point, correcting the core body temperature deviation that results from excessive PGE2 activity in the brain.

Complementary Dual Enantiomer Action

Flurbiprofen is a racemic compound whose two enantiomers contribute a distinct mechanistic dimension. While the S-enantiomer handles the main COX inhibition, the R-enantiomer engages a non- COX pathway by inhibiting the MRP4 transporter. This complementary activity affects PG dynamics at multiple points, leading to an alteration in PG signaling dynamics within the targeted pathways.

How to Use Majezik-SR

Majezik-SR (Flurbiprofen sustained-release) is a medication with specific administration guidelines. The sustained-release formulation is intended for oral use, meaning the tablet is administered by mouth.

Official Dosing and Frequency

The standard adult dosing regimen for the sustained-release form is typically a single, fixed dose of 200 mg taken once daily. This once-daily frequency is essential to leverage the prolonged-release characteristics of the formulation, which is designed to maintain consistent therapeutic levels over a 24-hour period. Standard clinical parameters emphasize that any NSAID should be used at the lowest effective dosage for the shortest necessary duration consistent with treatment goals.

Administration Requirements and Constraints

The administration of the Majezik-SR tablet is subject to important physical constraints. Due to its engineered design, the sustained-release tablet must be swallowed whole. The tablet should not be crushed, broken, or chewed, as disrupting the integrity of the tablet compromises the controlled-release mechanism and can lead to the rapid release of the entire dose.

The medication may be taken with or without food; however, administration with a full glass of water or food is often advised to help mitigate the potential for gastrointestinal irritation.

Dose Adjustment and Special Populations

Dosing may require special consideration for certain patient populations. Clinical parameters indicate that reduced dosages may be necessary for patients with known or suspected renal or hepatic impairment, and the drug's use is not generally established for the pediatric population. If a dose is missed, it should be taken as soon as it is remembered unless it is near the time of the next scheduled dose, in which case the missed dose should be skipped; doubling a dose is not permitted.

Research evidence / Overview of studies for Majezik-SR

The clinical evidence for Majezik-SR (Flurbiprofen sustained-release) is primarily derived from studies observing symptom patterns in conditions associated with inflammatory or irritative states. Research has examined the patterns of symptom change in adult patients through randomized controlled trials and subsequent scientific reviews.

Evidence for Symptomatic Relief in Rheumatoid Arthritis

Research examined the medicine in conditions characterized by fluctuating or unstable symptoms, such as Rheumatoid Arthritis (RA), using RCTs and Systematic Reviews. Studies explored adult patients with symptomatic RA, monitoring outcomes describing episodic or acute changes in articular pain and joint swelling. Findings describe patterns observed when contrasted with placebo or standard alternative treatments, contributing to understanding symptom patterns over the short term. Follow-up durations were limited, typically a median of four weeks. Research was generally not designed to assess long-term systemic outcomes in populations studied for chronic RA.

Evidence for Symptomatic Relief in Osteoarthritis

The medicine was observed in conditions of heightened symptoms, specifically Osteoarthritis (OA). Studies used RCTs in adult populations, examining outcomes reflecting daily functioning and pain in joints like the knee or hip. Data show patterns related to measured changes in joint pain and tenderness when contrasted with other treatments. Trials typically extended for six weeks. The available studies are designed to explore short- to intermediate-term changes in measured outcomes, providing limited insight into the full scope of long-term use.

Evidence for Acute Symptom Management

Research explored the medicine in trials assessing short-term or episodic symptom patterns, such as those associated with Dysmenorrhea. Studies employed RCTs, monitoring outcomes describing episodic changes in the intensity of physical discomfort. The main limitation is the short-term nature of the designs. Data for the specific sustained-release formulation often requires extrapolation from studies that utilized the immediate-release form.

Evidence in Specific Patient Groups and Uncertainty

Study populations for the core evidence are primarily the general adult population. Evidence is limited regarding outcomes in special groups, such as pediatric patients or pregnant populations. The comparative evidence is lacking for some outcomes, and data for certain specific groups, such as those with particular comorbidities, remain insufficient. Follow-up durations were limited for chronic conditions, meaning that long-term effects on the progression of chronic conditions are not fully established.

Key Studies & References Flurbiprofen (Flurbiprofen Systemic): MedlinePlus Drug Information (A687005)

Common questions about Majezik-SR (FAQ)

Q: What is Majezik-SR used for?

Majezik-SR is a medicine used to relieve pain, swelling, and inflammation caused by certain conditions. It is commonly prescribed for chronic diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also used for the treatment of acute painful conditions.

Q: How should I take Majezik-SR?

Take Majezik-SR exactly as your doctor prescribes. Typically, Majezik-SR is a slow-release or sustained-release tablet, meaning it is designed to release the medicine gradually over time. You should swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet, as this can affect the way the medicine works and may increase the risk of side effects. It is usually recommended to take this medication with food or milk to help prevent stomach upset.

Q: What should I do if I miss a dose of Majezik-SR?

If you miss a dose of Majezik-SR, take it as soon as you remember, unless it is almost time for your next scheduled dose. If it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are unsure, you should consult with your healthcare provider.

Q: Can I drink alcohol while taking Majezik-SR?

It is generally advised to limit or avoid alcohol consumption while taking Majezik-SR. Drinking alcohol while taking this medication can increase the risk of stomach bleeding and other gastrointestinal side effects. Discuss your alcohol intake with your doctor.

Q: What are the common side effects of Majezik-SR?

Like all medicines, Majezik-SR can cause side effects, although not everyone gets them. Common side effects may include:

• Stomach upset or pain
• Nausea
• Indigestion (dyspepsia)
• Headache
• Dizziness

Contact your doctor if any of these side effects are persistent or bothersome. If you experience serious side effects, such as signs of bleeding, severe allergic reactions, or heart problems, seek medical attention immediately.

Q: How long does it take for Majezik-SR to start working?

Majezik-SR is designed for sustained release, meaning the full pain-relieving effects may take some time to become noticeable. While some people may feel relief within a few hours, the maximum therapeutic benefit for chronic conditions like arthritis may take several days to a few weeks of regular use. It is important to continue taking the medication as prescribed, even if you do not feel immediate relief.

How to Store and Dispose of Majezik-SR?

The official storage and disposal guidelines for Majezik-SR (Flurbiprofen) ensure product stability and safety in the home.

Storage Requirements

Storage Factor	Official Guideline
Temperature	Store at room temperature.
Protection	Store away from excess heat, moisture, and direct light. Do not allow the medication to freeze.
Container	Keep the medicine in its original, tightly closed container.
Accessibility	Keep out of the reach and sight of children to prevent accidental ingestion.

Disposal Guidelines

To dispose of unused, outdated, or no longer needed medicine, do not flush it down a toilet or pour it down a drain unless specifically instructed to do so. It is necessary to ask a healthcare professional or pharmacist about the proper disposal methods in your community, which often include medicine take-back programs.